APA (7th ed.) Citation

Mithoefer, M., Mithoefer, A., Feduccia, A., Jerome, I., Wagner, M., Hoilland, J., . . . Doblin, R. (2019). S.08.06 MDMA-assisted psychotherapy for PTSD: A promising novel experimental treatment moving into phase 3 trials with FDA breakthrough therapy designation. European Neuropsychopharmacology, 29, S11. https://doi.org/10.1016/j.euroneuro.2018.11.930

Chicago Style (17th ed.) Citation

Mithoefer, M., et al. "S.08.06 MDMA-assisted Psychotherapy for PTSD: A Promising Novel Experimental Treatment Moving into Phase 3 Trials with FDA Breakthrough Therapy Designation." European Neuropsychopharmacology 29 (2019): S11. https://doi.org/10.1016/j.euroneuro.2018.11.930.

MLA (9th ed.) Citation

Mithoefer, M., et al. "S.08.06 MDMA-assisted Psychotherapy for PTSD: A Promising Novel Experimental Treatment Moving into Phase 3 Trials with FDA Breakthrough Therapy Designation." European Neuropsychopharmacology, vol. 29, 2019, p. S11, https://doi.org/10.1016/j.euroneuro.2018.11.930.